Ohio is currently home to 3211 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT06287775
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell grow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2025
Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio
Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT05803382
Recruiting
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2025
Locations: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
Register for Updates
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT05411094
Recruiting
This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Locally Advanced Pancreatic Carcinoma, Unresectable Pancreatic Carcinoma
Register for Updates
A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
NCT06967181
Recruiting
The purpose of this trial is to evaluate the safety and immunogenicity of CVM150 and CVM26. The trial will enroll up to 60 healthy participants.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio
Conditions: Mumps
Register for Updates
Addiction Potential of Very Low Nicotine Filtered Little Cigars
NCT06630728
Recruiting
The goal of this clinical trial is to learn how reducing the nicotine content in filtered little cigars can affect the the use of these cigars and lung health in current adult filtered little cigar users. The main question\[s\] it aims to answer are: Are puffing behaviors, appeal/satisfaction, craving suppression, pharmacokinetic effects, and demand similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars? Are health effects and... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/06/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Smoking (Tobacco) Addiction
Register for Updates
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: The Lindner Research Center at The Christ Hospital, Cincinnati, Ohio
Conditions: Coronary Artery Disease
Register for Updates
Targeted Pediatric High-Grade Glioma Therapy
NCT05839379
Recruiting
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.
Gender:
ALL
Ages:
Between 12 months and 39 years
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
Register for Updates
LGMD R1 Natural History Study
NCT05618080
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Register for Updates
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
NCT05400109
Recruiting
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Non Hodgkin Lymphoma
Register for Updates
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05286788
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT05278208
Recruiting
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Register for Updates